Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

This study will determine if docetaxel will be administered before or after doxorubicin/cyclophosphamides in an adjuvant chemotherapy regimen to be evaluated in a subsequent phase III trial.

Key facts

Study ID

NCT00201708

Run by

Ohio State University Comprehensive Cancer Center

People needed

56

Starts

2004-10-01

Expected to finish

2014-02-01

Last updated by the study team

2016-09-02

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Must have histologically or cytologically confirmed breast cancer
• No metastatic disease
• Prior lumpectomy or mastectomy
• No prior chemotherapy or hormone treatments for breast cancer
• Must have normal organ and marrow function.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

You may not qualify if…

• Peripheral neuropathy of grade II or higher.
• History or evidence upon physical exam of CNS (central nervous system Diseases)disease.
• History of unstable angina or myocardial infarction within the last six months.
• Pregnant or nursing women.
• Known allergies to polysorbate 80.
• HIV-positive patients.

Where it is running

• Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.